Coronavirus TV Episode 9: (Hydroxy)chloroquine, againMuch of the drug development news surrounding COVID-19 continues to be dominated by the malaria drugs chloroquine and hydroxychloroquine, with the US FDA providing a controversial emergency use authorization. This episode explores the known evidence for the drug and some of the ongoing development work that may yield firm clinical data over the coming months.
Coronavirus TV Episode 8: Gilead’s expanded accessStruggling under the weight of individual compassionate use requests, Gilead is scaling up its expanded access scheme for remdesivir ahead of an all-important data readout in April. Physicians and hospitals will be able to apply for multiple patients at once, accelerating access and enabling open-label data collection, adding real-world data to the clinical evidence base.
Coronavirus TV Episode 7: Sobering predictionsOver the weekend, Dr Fauci shared the latest models that project total mortality due to COVID-19 in the US of 100–200k, while slowing growth of new cases in Europe has yet to translate into reduced numbers of deaths. Day-to-day fluctuations and lagging indicators make it difficult to quantify the effect of social measures and potential therapeutic interventions.
Coronavirus TV Episode 6: COVID-19 Therapeutics AcceleratorNovartis is the latest company to join the collaboration initiative, spearheaded by the Bill and Melinda Gates Foundation. The accelerator is designed to act with central oversight into the collective efforts of industry and other partners, to expedite the development and availability of medicines for treating the COVID-19 pandemic.
Coronavirus TV Episode 5: Transitioning from R&D ethically
As the forerunner in COVID-19 R&D, all eyes are on Gilead as it navigates through R&D but also acts as a commercial entity. So far, it is making all the right moves such as giving up Orphan Drug status, building goodwill for the industry, although pharma’s detractors are never far away.
Coronavirus TV Episode 4: Digital ASCO
The 40k+ ASCO annual meeting, like many other industry conferences, is going online only. Some aspects of the digital experience may prove popular, although doctors and the influence of sponsors will likely bring a return to normality once the coronavirus outbreak is brought under control.
Coronavirus TV Episode 3: Eli Lilly and trial postponements
Eli Lilly has announced that most of its 300 ongoing or planned trials will be postponed to new patients, citing the pressure of COVID-19 on healthcare systems. A sensible step that many peers will follow, although the industry needs to evolve and incorporate decentralized trials to protect R&D momentum in the future.
Coronavirus TV Episode 2: Anti-malarials and Presidential endorsements
A small clinical trial in France suggests that hydroxychloroquine is an effective treatment for COVID-19. This episode dissects the hype surrounding the use of anti-malarials, and why rushing to adopt these drugs in hospitals globally may do more harm than good
Coronavirus TV Episode 1: Anti-viral developments
As the COVID-19 pandemic threatens to overwhelm hospitals, there is an immediate need for anti-virals to manage the growing numbers of patients. Using pharmaceutical industry pipeline data, this blog discusses where the most likely effective treatment will come from.
68 Total results for product and free and sample content found
News from around the biopharma sector and its efforts to meet the challenges posed by the coronavirus pandemic.
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.
A $2.2tn coronavirus stimulus package signed into law by President Trump on 27 March will distribute billions of dollars to federal agencies – including the FDA, the CDC and the FEMA – to hasten approvals of new diagnostics, medical ventilators, respirators and other medtech supplies, conduct more testing of potential COVID-19 patients, and quickly distribute medical supplies where needed most.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
Pharmaceutical manufacturing in India is facing some early stress amid the new 21-day lock-down but both the industry and government machinery are actively engaged and working together to ensure that disruptions are minimized in the ‘pharmacy of the world.’
AlloVir/Baylor, Soligenix/Hawaii and CEL-SCI/Georgia ink coronavirus collaborations, but deal-making continues in other areas as well, including Asklepios/UNC teaming on a gene therapy for Angelman syndrome and DeMelle licensing a targeted pancreatic cancer drug from Moffitt, among others.
Regeneron's head of R&D George Yancopoulos delivers some stirring words about the need to unify against the global threat posed by COVID-19.
No Records Found
COVID-19 PHARMA TRACKER
The latest coronavirus updates and developments impacting the global pharmaceutical supply chain, developed by CPhI
CPhI North America goes Digital
This May, CPhI is launching 5 days of content-rich webinars to provide the pharmaceutical industry with the essential information needed for a fast-changing world. Designed for the needs of remote workers, this will be a week of important content from industry experts.
Join Informa Pharma Intelligence as we kick off the week on May 4th at 11AM EDT with the webinar The response of Pharma and Biopharma to the Covid-19 Pandemic.
Watch the recorded panel discussions address the Covid-19 pandemic from BIO-Europe Spring, delivered digitally from March 23-27, 2020
The Covid-19 pandemic is creating unprecedented Healthcare challenges with far reaching effects yet to be measured. There is a need for greater collaboration and communication among researchers, healthcare systems, government agencies, NGOs, and the public at large. Behind the scenes, the biopharma industry is rallying to innovate and collaborate to develop diagnostics, vaccines and treatments as quickly as possible.
Coronavirus disease 2019 (COVID-19) is a highly infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first cases of COVID-19 were documented in China at the end of 2019 and now in 2020 this disease has spread to become a global pandemic.
As COVID-19 is a new disease, investigations are still ongoing to fully understand it and develop a vaccine. Spread of the disease is thought to be transmitted via respiratory droplets through coughing or sneezing, and can result in a variety of symptoms. It primarily targets the respiratory system with mild symptoms ranging from fever and cough to more severe cases where dyspnea and pneumonia can develop resulting in the need for respiratory assistance.
This disease is affecting us all globally but there are measures we can all take as individuals to fight COVID-19 so it is critical to follow government guidelines to stay safe and prevent COVID-19 from spreading.
The latest COVID-19 developments from Informa Pharma Intelligence
HBW Insight brings you vital news and analysis on how the coronavirus is impacting the health, beauty, and wellness business. Get insights into how the pandemic is affecting product lifecycles and overall industry growth with articles including:
Go behind the headlines with Pink Sheet to understand the impact the coronavirus is having on a global level, and how it is affecting policy and regulatory matters around the world. Explore more with articles including:
Scrip brings you updates on the latest coronavirus developments. See what’s in the pipeline, what progress is being made toward treatment and vaccines, and more, with articles including:
Medtech Insight takes you behind the headlines to understand how the medtech industry is coping with increased demands for diagnostics as the coronavirus has reached global pandemic proportions. Keep up with the latest developments with articles like:
In Vivo brings you an overview of how the global coronavirus pandemic is affecting business in the pharma and meddevice sectors. Download “Fact File: Coronavirus Pipeline And Corporate Updates” for insights into: